Citadel Advisors
AARD

Citadel Advisors’s Aardvark Therapeutics AARD Stock Holding History

Citadel Advisors’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$340K Buy
59,100
+6,200
+12% +$29K ﹤0.01% 10836
2026
Q1 		$199K Buy
+52,900
New +$548K ﹤0.01% 11423

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors's AARD Position: Q2 2026 in Review

Citadel Advisors increased its Aardvark Therapeutics (AARD) stake by 3.2% in Q2 2026, buying an estimated $189K and bringing the position to 1,283,166 shares worth $7.39M. The position accounts for ﹤0.01% of the portfolio, ranked #4060.

Citadel Advisors first reported a position in AARD in Q1 2025 and has held it in 6 quarters since. The position peaked at $18.1M in Q3 2025. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • Citadel Advisors held 1,283,166 shares of Aardvark Therapeutics worth $7.39M as of Q2 2026.
  • Citadel Advisors bought 40,389 Aardvark Therapeutics shares in Q2 2026, an estimated $189K.
  • Aardvark Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4060 holding.
  • Citadel Advisors first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Citadel Advisors's Aardvark Therapeutics position peaked at $18.1M in Q3 2025.
  • 71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.